Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation
Launched by MEDSTAR HEALTH RESEARCH INSTITUTE · Apr 16, 2013
Trial Information
Current as of June 17, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject \> 18 years of age;
- • Subject, male or female, who underwent DES or BMS implantation in a native coronary vessel more than 3 year ago;
- • Subject is scheduled for a diagnostic coronary or interventional procedure;
- • Subject is willing to sign the informed consent.
- Exclusion Criteria:
- • Subject requires emergency catheterization;
- • Subject has an acute myocardial infarction defined as anginal symptoms with ST-elevation on the EKG or creatine kinase-MB elevation \>3times the upper limit of normal;
- • Angiographic evidence of ≥ 70% stenosis within the target stent (visual estimate);
- • Subject presented with cardiogenic shock;
- • Subject has angiographically confirmed thrombus in the target coronary artery;
- • Subject has a complex lesion not amenable to the IVUS/VH catheters and/or OCT catheters passing the stented segment;
- • Subject has a contraindication to angiography/IVUS/OCT;
- • Female subject is pregnant or lactating;
- • Subject has life threatening comorbid conditions for which the investigator feels the subject should not be enrolled
About Medstar Health Research Institute
MedStar Health Research Institute (MHRI) is a leading clinical research organization affiliated with MedStar Health, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a robust portfolio of clinical trials across various therapeutic areas, MHRI collaborates with healthcare professionals, academic institutions, and industry partners to facilitate the development of new treatments and interventions. The institute is committed to maintaining the highest standards of ethical conduct and scientific rigor while fostering a culture of inquiry that enhances the health and well-being of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Ron Waksman, MD
Principal Investigator
Medstar Health Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials